Jostein Nordeng

Publication Activity (10 Years)

Years Active: 2021-2022
Publications (10 Years): 5

Top Topics

Nlrp Inflammasome

Top Venues

Journal of immunology research

Mediators of inflammation

This page only lists publications with an associated author ORCID identifier.

Publications

Trine Baur Opstad, Jostein Nordeng, Alf-Aage R Pettersen, Sissel Åkra, Vibeke Bratseth, Hani Zaidi, Ragnhild Helseth, Svein Solheim, Ingebjørg Seljeflot
The NLRP3 Genetic Variant (rs10754555) Reduces the Risk of Adverse Outcome in Middle-Aged Patients with Chronic Coronary Syndrome. Journal of immunology research 2022 (2022)
Trine Baur Opstad, Jostein Nordeng, Alf-Aage R Pettersen, Sissel Åkra, Vibeke Bratseth, Hani Zaidi, Ragnhild Helseth, Svein Solheim, Ingebjørg Seljeflot
The NLRP3 Genetic Variant (rs10754555) Reduces the Risk of Adverse Outcome in Middle-Aged Patients with Chronic Coronary Syndrome. Journal of immunology research 2022 (2022)
Vibeke Bratseth, Jostein Nordeng, Ragnhild Helseth, Svein Solheim, Sissel Åkra, Harald Arnesen, Gemma Chiva-Blanch, Ingebjørg Seljeflot
Circulating Microvesicles in Association with the NLRP3 Inflammasome in Coronary Thrombi from STEMI Patients. Biomedicines 10 (9) (2022)
Trine Baur Opstad, Jostein Nordeng, Alf-Aage R Pettersen, Sissel Åkra, Vibeke Bratseth, Hani Zaidi, Ragnhild Helseth, Svein Solheim, Ingebjørg Seljeflot
The NLRP3 Genetic Variant (rs10754555) Reduces the Risk of Adverse Outcome in Middle-Aged Patients with Chronic Coronary Syndrome. Journal of immunology research 2022 (2022)
Jostein Nordeng, Hossein Schandiz, Svein Solheim, Sissel Åkra, Pavel Hoffmann, Borghild Roald, Bjørn Bendz, Harald Arnesen, Ragnhild Helseth, Ingebjørg Seljeflot
The Inflammasome Signaling Pathway Is Actively Regulated and Related to Myocardial Damage in Coronary Thrombi from Patients with STEMI. Mediators of inflammation 2021 (2021)